Nimenrix remains free on the NIP for other eligible groups.
The MenQuadfi meningococcal ACWY vaccine is now available free under the National Immunisation Program to children aged 14-16 and those aged 15-19 who are catching up on missed vaccination, replacing Nimenrix for this cohort.
There are no changes for other cohorts. Nimenrix (one dose) is still funded under the NIP for children aged 12 months and for people of all ages with asplenia and hyposplenia, complement deficiency, and those receiving treatment with eculizumab.
It is still recommended that healthy children receive one dose of meningococcal ACWY vaccine at 12 months, and one dose between the ages of 14 and 19. People with specified immune conditions are recommended to have extra doses.
Meningococcal B vaccine is still only funded through the national program for Aboriginal and Torres Strait Islander children aged two months or more and people aged two months or more with certain medical conditions that increase their risk of invasive meningococcal disease. South Australia and Queensland separately fund meningococcal B vaccination (two doses) for babies and teenagers.
Related
Adolescents across the country can access the meningococcal ACWY vaccine through school programs, or through GPs, other health practitioners and pharmacies. It is mandatory to report all administered vaccines to the Australian Immunisation Register (AIR).
